Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2013 / Cilt: 19 - Sayı: 1

Etanercept - can it be used in the treatment of endotoxemia?

Etanersept - endotoksemi tedavisinde kullanılabilir mi?

Pages
133–139
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, when protective effect of etanercept on the heart and increasing effect on the interleukin-10 levels in the endotoxemia is considered, single dose etanercept may be beneficial in the veterinary medicine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim of this study was to investigate that effect of etanercept administration on the concentrations of cytokines, fibrinogen, antithrombin, 13,14-dihydro-15-keto-prostaglandin F2α and biochemical values in the endotoxemia.
📊
Key Findings & Data:A totally male 126 Sprague Dawley rats were divided 3 equal groups; lipopolysaccharide (4 mg, IP), etanercept (8 mg/kg, IP) and lipopolysaccharide + etanercept were administered to Group 1, 2, and 3, respectively.
💡
Conclusion & Impact:In conclusion, when protective effect of etanercept on the heart and increasing effect on the interleukin-10 levels in the endotoxemia is considered, single dose etanercept may be beneficial in the veterinary medicine.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:tümör nekroz faktör · alanin aminotransferaz · alkalin fosfotaz

Abstract

Aim of this study was to investigate that effect of etanercept administration on the concentrations of cytokines, fibrinogen, antithrombin, 13,14-dihydro-15-keto-prostaglandin F2α and biochemical values in the endotoxemia. A totally male 126 Sprague Dawley rats were divided 3 equal groups; lipopolysaccharide (4 mg, IP), etanercept (8 mg/kg, IP) and lipopolysaccharide + etanercept were administered to Group 1, 2, and 3, respectively. Blood samples were collected at 0, 1, 2, 4, 8, 12 and 24th hours after treatments. Serum tumor necrosis factor-α, interleukin-1β, interleukin-10 and plasma 13,14-dihydro-15-keto-prostaglandin F2α levels were measured with ELISA reader, while antithrombin and fibrinogen levels were measured with coagulometer. Serum biochemical parameters were determined with auto-analyzer. Etanercept had irregular effect on the fibrinogen levels and it increased PGM, alkaline phosphatase and alanine aminotransferase activities. Lipopolysaccharide increased cytokines, PGM, fibrinogen, organ damage markers and triglyceride levels, and it had irregular effect on the antithrombin levels. Increased cytokines, PGM and fibrinogen levels were determined in lipopolysaccharide + etanercept group, but irregular changes were observed in antithrombin levels. Etanercept exactly depressed the increased creatine kinase-MB level and relatively depressed the increased tumor necrosis factor-α while it extended the presence of tumor necrosis factor-α, and it increased the elevated interleukin-10 levels by lipopolysaccharide. In conclusion, when protective effect of etanercept on the heart and increasing effect on the interleukin-10 levels in the endotoxemia is considered, single dose etanercept may be beneficial in the veterinary medicine.

Özet

Araştırmanın amacı endotoksemide etanersept uygulamasının kan sitokinler, fibrinojen, antitrombin, 13,14-dihidro-15-keto prostaglandin F2α ve biyokimyasal parametrelere etkisini araştırmaktır. Erişkin 126 adet Sprague Dawley ırkı erkek rat 3 gruba ayrılarak; 1. Gruba lipopolisakkarit (4 mg, IP), 2. Gruba etanersept (8 mg/kg, IP) ve 3. Gruba lipopolisakkarit + etanersept uygulamaları yapıldı. Uygulamalardan sonra 0., 1., 2., 4., 8., 12. ve 24. saatlerde kan örnekleri alındı. Serum tümör nekrozis faktör-α, interlöykin-1β, interlöykin-10 ve plazma 13,14-dihidro-15-keto-prostaglandin F2α düzeyleri ELISA okuyucusunda; sitratlı plazma antitrombin ve fibrinojen düzeyleri koagulometrede; serum biyokimyasal parametreleri otoanalizörde belirlendi. Etanerseptin fibrinojen düzeyinde düzensiz değişimlere ve 13,14-dihidro-15-keto-prostaglandin F2α, alkalen fosfataz ile alanin aminotransferaz düzeyinde yükselmelere neden olduğu belirlendi. Lipopolisakkarit uygulaması sitokinler, 13,14-dihidro-15-keto-prostaglandin F2α, fibrinojen, organ hasar belirteçleri ve trigliserit düzeylerinde yükselmelere neden olurken, antitrombin seviyesinde düzensiz değişimlere neden oldu. Lipopolisakkarit + etanersept uygulanan grupta sitokinler, 13,14-dihidro-15-keto-prostaglandin F2α ve fibrinojen düzeyinde yükselmeler, antirombin düzeyinde düzensiz değişimler gözlendi. Lipopolisakkarit uygulaması ile yükselen kreatin kinaz-MB düzeyinin etanersept tarafından tamamen, tümör nekrozis faktör-α yükselmesinin kısmen engellendiği ancak kanda kalış süresini uzattığı ve interlöykin-10 düzeyini daha fazla yükselttiği belirlendi. Sonuç olarak endotoksemide etanerseptin kalp üzerindeki koruyucu etkisi ve interlöykin-10 düzeyini yükseltmesi nedeni ile tek doz uygulamasının veteriner sahada faydalı olabileceği belirlendi.

🔖

Cite This Article

ER, A., DIK, B., ÇETİN, G., ALTAN, F., ÜNEY, K., ELMAS, M., YAZAR, E. (2013). Etanercept - can it be used in the treatment of endotoxemia?. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 19 - Sayı: 1, 133–139. https://ajindex.com/articles/274148

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Van Amersfoort ES, Van Berkel TJ, Kuiper J: Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev, 16, 379-414, 2003
  2. Lopez-Bojorquez LN, Dehesa AZ, Reyes-Teran G: Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res, 35, 465-479, 2004
  3. Opal SM: The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol, 297, 365-377, 2007
  4. Buttenschoen K, Radermacher P, Bracht H: Endotoxin elimination in sepsis: Physiology and therapeutic application. Langenbecks Arch Surg, 395, 597-605, 2010
  5. Davies B, Cohen J: Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis, 11, 65-71, 2011
  6. Er A, Yazar E: Effects of macrolide antibiotics on blood inflammatory mediators and organ damage markers in lipopolysaccharide-induced pulmonary damage rats. Eurasian J Vet Sci, 26, 7-13, 2010
  7. Coskun A, Sen I: Acute phase response and clinical changes in calves with lipopolysaccharide induced endotoxemia. Eurasian J Vet Sci, 28, 21-26, 2012
  8. Reimold AM: New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci, 325, 75-92, 2003
  9. Karabacak A, Yazar E: Current approaches in the treatment of septic shock. Eurasian J Vet Sci, 22, 95-103, 2006
  10. Ganidagli S, Gedik R, Koruk S, Mizrak A: Yoğun bakımda koagülasyon. TAD, 6, 36-44, 2008
  11. Kaya S: Narkotik olmayan ağrı kesiciler. In, Kaya S, Pirinçci İ, Bilgili A (Eds): Veteriner Hekimliğinde Farmakoloji
  12. Baskı, s. 373-400, Medisan Yayınları, Ankara, 2002
  13. Basu S, Eriksson M. Oxidative injury and survival during endotoxemia. FEBS Lett, 438, 159-160, 1998
  14. Altan F, Elmas M, Er A, Uney K, Cetin G, Tras B, Yazar E: Effects of drugs on kinetic values of cytokines, adenosine deaminase and 13,14-dihydro-15-keto-prostaglandin F2α in endotoxemia: A different approach. Eurasian J Vet Sci, 26, 15-19, 2010
  15. Yazar E, Er A, Uney K, Bulbul A, Avci GE, Elmas M, Tras B: Effects of drugs used in endotoxic shock on oxidative stress and organ damage markers. Free Radic Res, 44, 397-402, 2010
  16. Turgut K: Karaciğer hastalıkları ve testleri-Endokrin, metabolik ve lipid bozuklukları ve testleri. In, Veteriner Klinik Laboratuar Teşhis
  17. Baskı. s. 202-486, Bahçıvanlar Basım Sanayi, Konya, 2000
  18. Yurt AO: Effect of meloxicam on serum vitamin and cytokine levels during endotoxemia. Eurasian J Vet Sci, 28, 47-53, 2012. 1